of the CVProfilor^® DO-2020 CardioVascular Profiling System. Since then, we have introduced our technology at the Annual Meeting of the American College of Physicians - American Society of Internal Medicine (ACP-ASIM) held in Atlanta, GA and at the American College of Cardiology in Orlando, FL. At the same time, we successfully recruited a number of talented and experienced individuals to fill key management positions that will directly support the future sales growth of our CVProfilor^® System.”

“We are beginning to see acceptance of our pricing, marketing and reimbursement expectations for the CVProfilor^®. As a result, we have added to the professional organization we had in place to fully capitalize on the opportunities we see in the large market of physicians, clinics and healthcare facilities throughout the United States,” Guettler said.

New management appointments announced today by HDI include:

• E. Paul Maloney, Vice President-Engineering;

• Frank Tappen, Director of U.S. Sales;

• Jeff Tonkinson, Director of Software Engineering;

• Roxanne “Rocky” DeMarre, Customer Service Manager;

• Dan Costelloe, Northwest Regional Sales Manager;

• Paul Quinn, Southwest Regional Sales Manager.

“Each new member of our team brings to HDI extensive experience in their area of responsibility and a proven track record of accomplishment that will enable us to capitalize on our aggressive expectations for growth,” Guettler said. “With Regional Sales Managers already in place for the Midwest and Southeast Regions, we are now almost fully staffed to take the distribution of our proven technology to the next level. We intend to announce the addition of one to two regional sales managers for the northeast soon.”

“We are pleased with the reception that our CVProfilor^® technology received at the two medical conferences in which we recently participated. For example, at the ACP-ASIM meeting in Atlanta, we conducted more than 200 demonstration tests reflecting a high level of interest on the part of the physicians who reviewed our technology. Over the next six weeks, we will demonstrate the CVProfilor^® at the Sixteenth Scientific Meeting and Exposition of the American Society of Hypertension in San Francisco and the 61st Scientific Sessions of the American Diabetes Association in Philadelphia. Both of these prestigious conferences represent an ideal setting to further extend the visibility of our proven technology which has been cleared for marketing by the FDA,” Guettler said.

New Management Team Members
E. Paul Maloney, newly appointed Vice President-Engineering, joined HDI with responsibility for overseeing all aspects of the Company’s design, development and engineering support for current and new medical device products. During the previous ten years, Maloney was President and Chief Engineer of Solutions Engineering, Inc., a firm he owned and operated which provided engineering services to several medical device companies, including HDI. Mr. Maloney has held engineering positions with escalating managerial duties at Honeywell Avionics, TSI, Inc., Nicollet Instruments and Vasamedics, Inc., all within the Minneapolis-St. Paul area.

Frank Tappen, HDI’s new Director of U.S. Sales, was formerly National Sales Manager for St. Paul, MN-based Surgical Technologies, Inc. Prior to that assignment, Tappen served in a variety of increasingly responsible sales and sales management positions with Pfizer, Inc., United States Surgical Corporation, Johnson & Johnson and 3M.

Jeff Tonkinson has joined HDI as Director of Software Engineering. During the past 14 years, Tonkinson has been employed as a software and systems engineer at two Twin Cities-based companies. In 1987, he joined the Tennant Company and served as a Principle Engineer, designing and developing software systems for robotic floor maintenance equipment. From 1997 until 2001, he worked as a Software Engineer at Solutions Engineering, Inc. 

Roxanne “Rocky” DeMarre, newly appointed Customer Service Manager for HDI, was previously Customer Service Manager for GN ReSound, the second-largest hearing healthcare organization in the world. Prior to joining GN ReSound, DeMarre held various customer service, accounting and marketing positions in divisions of 3M.

Dan Costelloe, HDI’s newly appointed Northwest Regional Sales Manager, has most recently been responsible for medical equipment sales to physicians in the Pacific Northwest for a division of Medtronic, Inc. Prior to joining Medtronic, Costelloe held a variety of sales and clinical support positions for Boston Scientific, St. Jude Medical, Biotroniks, Marquette Electronics and Abbott Laboratories.

Paul Quinn, named to the position of Southwest Regional Sales Manager for HDI, has extensive sales and management experience holding positions with Baxter Healthcare, Johnson & Johnson, Steris Corporation and Cytyc Corporation. He was most recently responsible for sales and business development for Affinity, Inc., formerly Zanova, Inc.

About Hypertension Diagnostics
Hypertension Diagnostics, Inc. designs, develops, manufactures and markets proprietary cardiovascular profiling systems for clinical and research applications. These systems carry the Underwriters Labs label and the CE Mark of quality, and they are marketed to physicians, other health care professionals and researchers by a direct sales force and via distributors throughout the world. In addition to providing blood pressure values, the systems non-invasively detect subtle changes in the compliance or elasticity of both large and small arteries which is a unique feature of HDI’s blood pressure waveform analysis technology. The system includes a custom designed Arterial PulseWave™ Sensor to capture waveform data as well as a printer which generates a CVProfile™ Report which can assist physicians in their clinical work.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company's 2000 Annual Report on Form 10-KSB, as amended, under the caption “Risk Factors,” as well as others not now anticipated.

Hypertension Diagnostics, HDI/PulseWave™ and CVProfilor^® are trademarks of Hypertension Diagnostics, Inc. All rights reserved.

Contact: Greg H. Guettler, President